Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

STEMINA BIOMARKER DISCOVERY, INC.

Madison, WI US

STEMINA BIOMARKER DISCOVERY, INC. Patent applications
Patent application number	Title	Published
20110312019	Predicting Human Developmental Toxicity of Pharmaceuticals Using Human Stem-Like Cells and Metabolomics - The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.	12-22-2011
20110081675	Metabolic Biomarkers Of Drug-Induced Cardiotoxicity - The invention provides methods and biomarkers for assessing cardiac metabolic response to pharmaceuticals, environmental agents, chemical compounds and biologic therapies. The invention provides methods for identifying cellular metabolites secreted by primary cardiomyocytes, cardiomyocyte precursor cells, clonal cardiomyocytes derived from adult human heart, immortalized cardiomyocytes, human embryonic stem cell (hESC)-derived cardiomyocytes, human induced pluripotent stem cell (iPS)-derived cardiomyocytes, or any cell displaying cardiomyocyte-specific markers in response to exposure to pharmaceuticals, environmental agents, chemical compounds and biologic therapies that are cardiotoxic. Cardiomyocyte-secreted cellular metabolites provide metabolic signatures of cardiotoxicity, and can be used to screen pharmaceutical agents, lead and candidate drug compounds, biologics, and other therapeutics for cardiotoxic effects.	04-07-2011